NextCure Share Price
NASDAQ: NXTC | HealthcareNextCure Stock Performance
NextCure Share Price Chart
NextCure Quarterly Profit & Loss
All figures in USD
NextCure Annual Profit & Loss
All figures in USD
NextCure Balance Sheet
All figures in USD Million
NextCure Cash Flow
All figures in USD Million
Corporate Actions
About NextCure
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
NextCure Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Nov 2026 | $5.71 | $6.82 | +4.85% |
Oct 2026 | $5.13 | $6.50 | +27.70% |
Sep 2026 | $6.51 | $5.09 | -16.35% |
Aug 2026 | $4.32 | $6.08 | +48.41% |
Jul 2026 | $1.85 | $4.10 | +149.24% |
Jun 2026 | $5.77 | $1.65 | -73.60% |
May 2026 | $9.80 | $6.23 | -33.37% |
Apr 2026 | $11.28 | $9.35 | -10.40% |
Mar 2026 | $12.19 | $10.44 | -20.95% |
Feb 2026 | $11.14 | $13.20 | +20.55% |
Jan 2026 | $13.43 | $10.95 | -23.80% |
Dec 2025 | $12.04 | $14.37 | +2.35% |